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DissolutionAbstract In the study, self emulsifying drug delivery system (SEDDS) of gliclazide, a poorly soluble
drug, was developed and evaluated by in-vitro, ex-vivo and in-vivo techniques. Oil and surfactant were
screened out according to their solubilizing capacity. Among the tested components Transcutol HP
and Tween-80 showed good solubilizing capacity. These two components were used in different ratios
to prepare gliclazide SEDDS. The SEDDS formulations were transparent and clear. Droplet size of
the emulsion was determined by Laser Diffraction Technology of Malvern. Formulation F1 contain-
ing 1:1 (m/m) mixture of Transcutol HP/Tween-80 showed minimum mean droplet size (50.959 lm).
In-vitro drug release fromF1was higher (99%within 20 min) than other formulations. The developed
SEDDS was also evaluated for ex-vivo permeability proﬁle by using chicken intestinal sac. Formula-
tion F1 showed optimal drug diffusion. In-vivo performance of SEDDS was evaluated in albino mice
using plasma glucose level as a pharmacodynamic marker parameter. The test formulation (F1)
showed signiﬁcant reduction in plasma glucose level, after oral administration. So SEDDS may be
an alternative technique for the oral administration of gliclazide.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Drugs are most often administered by the oral route, but
approximately 40% of new drug candidates have poor-watersolubility and the oral delivery of such drugs is difﬁcult be-
cause of their low bioavailability, high intra- and inter-subject
variability, and a lack of dose proportionality. To overcome
these problems, various strategies are exploited including the
use of surfactants, lipids, permeation enhancers, microniza-
tion, salt formation, cyclodextrins, nanoparticles and solid dis-
persions (Kumar et al., 2010; Aungst, 1993). Majority of these
approaches have their limitations because of the need for
specialized equipment, a complicated manufacturing process,
longer processing time, and regulatory complexity. Lipid-
based formulation approaches, particularly the self emulsify-
ing drug delivery system (SEDDS), are well known for their
potential as an alternative approach for the delivery of
Table 1 Formulation of SEDDS of gliclazide. (Different
ratios of surfactants and co-surfactants containing 500 mg
capryol 90).
Name F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg)
Gliclazide 10 10 10 10 10
Transcutol-HP 500 350 250 750 650
Tween-80 500 650 750 250 350
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poor water solubility and low oral bioavailability (Kim
et al., 2000).
SEDDSs are isotropic and thermodynamically stable solu-
tions consisting of oil, surfactant, co-surfactant and drug mix-
tures that spontaneously form oil-in-water (o/w) emulsions
when mixed with water under gentle stirring. The motility of
stomach and intestine provides the agitation required for
self-emulsiﬁcation in-vivo (Shah et al., 1994). Selection of a
suitable self-emulsifying formulation depends upon the assess-
ment of the solubility of the drug in various components and
the droplet size distribution of the resultant emulsion following
self-emulsiﬁcation (Kommuru et al., 2001).
Chemically gliclazide is [1-(3-azabicyclo(3,3,0)oct-3-yl)-3-p-
tolylsulfonylurea], it is a second generation hypoglycemic sul-
fonylurea which is useful in the treatment of non-insulin
dependent diabetes mellitus (NIDDM). Prior reports reveal
that the drug shows good tolerability, low incidence of hypo-
glycemia, and a low rate secondary failure (Harrower, 1994).
In addition, it has a potential for slowing the progression of
diabetic retinopathy. For the reasons stated gliclazide appears
to be a drug of choice in long term sulfonylurea therapy for the
control of NIDDM (Harrower, 1994). Gliclazide is a white
crystalline powder, relatively insoluble in water. The pKa of
gliclazide is 5.8. Gliclazide exhibits slow GI absorption rate
and inter individual variations of its bioavailability (Palmer
and Brogden, 1993). The slow absorption rate of the drug usu-
ally originates from either poor dissolution of drug from the
formulation or poor permeability of the drug across the GI
membrane.
The objective of the present work was to formulate a self-
emulsifying drug delivery system (SEDDS) for gliclazide. Oil
and surfactant were screened out according to their solubiliz-
ing capacity. Formulations were initially checked visually. Par-
ticle size of SEDDS formulation was determined by Laser
Diffraction Technology of Malvern. Isotropic systems were
then evaluated by in-vitro dissolution study.
SEDDS of gliclazide was further evaluated by ex-vivo per-
meability study as intestinal permeability represents one essen-
tial part in the prediction of oral bioavailability (Ginski and
Polli, 1999). A number of methods for assessing the intestinal
permeability of a given drug have been developed and re-
viewed (Ferrec et al., 1999). Isolated intestinal sacs of several
animal species including rat, rabbit, pig, dog, and monkey
can be used in permeability studies (Tukker, 2000). Irvine
et al. (1999) reported that the chicken small intestine could
be a useful model for intestinal absorption. Kale et al. (2007)
performed absorption studies of slow drug release formula-
tions by using the chicken intestine segment. Dias et al.
(2010) also used the chicken intestine segment to investigate
the effect of sodium lauryl sulfate as a permeation enhancer
for muco-adhesive acyclovir tablets. In this study we also used
the chicken intestine segment for permeability studies of glicla-
zide SEDDS based on the assumption that membrane perme-
ability of drugs is not species-dependant, since the composition
of plasma membrane of intestinal epithelial cells is similar
across the species.
Pharmacodynamic marker parameters are often used to
evaluate the performance of different classes of drugs. Patil
et al. (2007) evaluated the in-vivo performance of simvastatin
SEDDS in rats using pharmacodynamic marker parameters
like plasma total cholesterol (CH), triglycerides (TG) andhigh-density lipoprotein (HDL-CH) for 21 days. In this study
in-vivo performance of gliclazide SEDDS was evaluated in
mice using plasma glucose level as pharmacodynamic marker
parameters. Oral glucose loading animal model reported by
Etuk (2010) was used for in-vivo performance in this study.
2. Materials and methods
2.1. Materials
Gliclazide was a kind gift from General Pharmaceuticals Ltd,
Dhaka, Bangladesh. Transcutol HP, Labrafac lipophile WL
1349, Lauroglycol FCC, Maisine 35-1, Capryol PGMC, Lab-
raﬁil M1944Cs, Lauroglycol 90, Labrafac PG, Peceol, Plurol-
oleique CC497, Labraﬁl M2125Cs, Labrasol, and Capryol 90
were kind gifts from Gatoforese, France. Tween 80, and
Tween-20 were purchased from JHD Chemicals Ltd., India.
Other reagents were of analytical-reagent grade and purchased
from the local market. Water was deionised and double dis-
tilled. Marketed formulations of gliclazide tablet (denoted as
A and B) were purchased from the local drug store in Dhaka
city after checking their manufacturing license number, batch
number, production and expiry date.
2.2. Solubility analysis of gliclazide in various excipients
According to Ashok and Pradeep (2007) the following slightly
modiﬁed method was used to determine the solubility of glicla-
zide in various components (oil and surfactants). 1 gm of each
of the vehicleswasmixedwith 100 mg gliclazide in different glass
vials. After sealing, the system was mixed by using a vortex mix-
ture (Digisystem Laboratory Instruments Inc. Taiwan.). Then
the sampleswere sonicated (PowerSonic 505,HwashinTechnol-
ogy, Korea) to facilitate the solubilization. Samples were then
analyzed by HPLC to determine the solubility.
2.3. Formulation of SEDDS
To develop gliclazide SEDDS formulation, solubility of glicla-
zide in different oils, surfactants was determined. Among the
excipients Transcutol HP (60 mg/gm) and Tween-80 (40 mg/
gm) showed good solubilizing capacity. Various formulations
were prepared with a constant amount of gliclazide (10 mg)
and oil (Capryol 90 500 mg) with varying ratios of surfactant
and co surfactant (Table 1). In brief, accurately weighed glicla-
zide, Capryol 90 (500 mg as oil phase) was mixed in a mixture
of Transcutol HP (used as co-surfactant) and Tween-80 (used
as surfactant) in stoppered glass vials. Then the components
were mixed by gentle vortexing & sonicating until gliclazide
was properly dissolved. The prepared formulations were stored
at ambient conditions until further use.
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Gliclazide SEDDS formulations were visually examined for
clarity, homogeneity and color. To observe the color of the
formulations, normal visual examination was performed.
Screw-cap vials containing SEDDS formulations were kept
standing against light to examine the clarity. Presence or ab-
sence of precipitation was noticed to assess the homogeneity
of the prepared formulations. The SEDDS formulations were
then kept at optimum room temperature for 1 month. After
1 month, those properties of the SEDDS formulations were
again examined to determine the stability of the formulation
of gliclazide SEDDS.
2.5. Determination of droplet size of gliclazide SEDDS
Emulsion droplet size of SEDDS formula was determined by
laser Diffraction Technology of MAIVERN (Mastersizer,
2000) equipped with 2000 hydro MU with a particle range of
0.02–2000 lm. 0.5 ml of SEDDS formulations were diluted
with 50 ml buffer of pH 6.8. Then emulsion droplet size was
determined. Droplet size distribution was characterized with
the help of the droplet size distribution pattern.
2.6. In-vitro dissolution study of SEDDS formulation and
comparison with market products
In-vitro dissolution study of gliclazide and gliclazide SEDDS
was carried out in a USP Type II (paddle type) dissolution
apparatus (Electrolab, India). 10 mg of pure gliclazide and
SEDDS formulation equivalent to 10 mg of gliclazide were
ﬁlled in a hard gelatin capsule shell (size #0) prior to dissolu-
tion study. Phosphate buffer pH 6.8 was used as dissolution
medium that was maintained at 37 ± 0.5 C and stirred at
100 rpm. Dissolution samples were withdrawn at predeter-
mined time intervals. Each time 10 ml of the dissolution sam-
ple was withdrawn with a calibrated plastic disposable syringe
and the media were replenished with fresh phosphate buffer of
pH 6.8. Withdrawn samples were ﬁltered with 0.2 lm syringe
ﬁlter of Microswit (Hannover, Germany) and were analyzed
for drug content by HPLC. Two brands of immediate release
tablets were also included in this study for comparison.
2.7. Ex-vivo permeability study
Ex-vivo permeability study was carried out by using chicken
intestinal sacs. Chicken was killed and the duodenal part of
the small intestine was isolated and washed with distilled water
to remove the mucous and lumen content and then put into an
oxygen chamber. 3 cm long sacs were prepared by tying up the
two end of the sac with cotton thread. SEDDS formulation
equivalent to 10 mg gliclazide was taken inside the sac. Intesti-
nal sac containing only excipients and another sac containing
10 mg pure drug suspended in 1 ml water were also included
in this study for comparison. The sacs were then taken into dif-
ferent dissolution baskets containing 900 ml phosphate buffer
of pH 6.8 maintained at 37 ± 0.5 C and stirred at 100 rpm.
Samples were withdrawn at predetermined time intervals. Each
time 10 ml of the sample was withdrawn with a calibrated plas-
tic disposable syringe and media were replenished with freshmedium. The samples were analyzed by the HPLC method.
The permeability of gliclazide was checked for 5 h.
2.8. In-vivo performance study of SEDDS on glucose level of
albino mice
Six healthy mice were included in this study. 1 gm of glucose
was dissolved in 5 ml water. 100 ll of this solution was admin-
istered to each of the mice orally using a micro pipette and
blood samples were collected from mice tails and the glucose
level was checked using Bionime GM100 blood glucose meter
after 0, 30, 60, 90, 120, 150, 180 min. After seven days the
experiment was repeated by using glucose solution containing
pure gliclazide. 1 gm of glucose and 10 mg gliclazide were
mixed in 5 ml water. 100 ll of this mixture was administered
to each of the mice orally. Then blood samples were collected
from mice tails and checked for glucose level. The experiment
was again repeated after seven days as wash out period by
administering samples containing glucose and SEDDS formu-
lation (F1) of gliclazide in the same dose as mentioned above.3. Results and discussions
3.1. Solubility analysis of gliclazide in various excipients
Solubility of gliclazide in various components (oil and surfac-
tant) was studied for the selection of oil & surfactants. Among
the excipients Transcutol HP showed good solubilizing capac-
ity (60 mg/gm of oil). Solubility of gliclazide in Labrafac lipo-
phile WL 1349, Lauroglycol FCC, Maisine 35-1, Capryol
PGMC, Labraﬁil M1944Cs, Lauroglycol 90, Labrafac PG,
Peceol, PlurololeiqueCC497, Labraﬁl M2125Cs was less than
<20 mg/gm and in Labrasol, Capryol 90 was <30 mg/gm of
oil. Among the surfactants, Tween-80 showed good solubiliz-
ing capacity (40 mg/gm). These two excipients (Transcutol
HP and Tween-80) were used to prepare gliclazide SEDDS
with capryl 90 as oil phase. Solubility of gliclazide in various
media like buffer 1.2pH, 4.5pH, 6.8pH & distilled water, was
also studied for the selection of dissolution medium. Among
those media of pH 6.8 showed good solubilizing capacity
and was thus used as a dissolution medium.
3.2. Development of HPLC method for the analysis gliclazide
A Shimadzu (Japan) HPLC system consisting of a CMB-20
Alite system controller, two LC-20AT pumps, SIL-20A auto-
sampler and CTO-10ASVP column oven was used. Ultraviolet
detection was achieved with a SPD-20A UV–VIS detector
(Shimadzu, Japan). The drug analysis data were acquired
and processed using LC solution (Version 1.2, Shimadzu, Ja-
pan) software running under Windows XP on a Pentium PC.
Separation of the drug was achieved from C18 column (5 l,
4.6 · 150 mm, Waters, USA) at 30 C temperature with a mo-
bile phase consisting of acetonitrile: phosphate buffer (pH
2.24) (ratio:70:30) at a ﬂow rate of 1.5 ml/min. The method
was validated for the parameters like system suitability, selec-
tivity, linearity, accuracy, precision and robustness.
The system is found suitable in respect to retention
time (%RSD 0.179) and mean theoretical plate count
(%RSD 0.788). The absence of additional peaks of excipients
Figure 1 Formulations after preparation.
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the selectivity and speciﬁcity of the method. The linearity of
the method was determined at different concentration levels
(1–25 lg/ml, r2 = 0.998). For accuracy testing, six replicate
runs of samples containing excipients and drug were per-
formed. The % recovery value, which was 99.94 ± 0.67%,
indicated the accuracy of the method. Precision was deter-
mined by repeatability (intra-day) and intermediate precision
(inter-day) and assessed by %RSD (Table 2).
Finally robustness test was performed by changing the ﬂow
rate, column temperature and mobile phase composition and
no marked changes in the chromatograms were observed,
which demonstrated that the method was robust.
3.3. Physical properties of gliclazide SEDDS
SEDDS formulations were visually examined for clarity,
homogeneity and color (Fig. 1). All the SEDDS formulations
of gliclazide containing transcutol and tween-80 were transpar-
ent, homogenous and clear.
3.4. Emulsion droplet size analysis
Emulsion droplet size of SEDDS formulation was determined
by the Laser Diffraction Technology of Malvern (Mastersizer,
2000). Particle size distribution was characterized with the help
of droplet size distribution of 10% particles – d (0.1), droplet
size distribution of 50% droplet – d (0.5), and droplet size dis-
tribution of the 90% particles – d (0.9). Droplet size range of
the SEDDS formulation of system I–V was in the range of
9.10 lm to 246.444 lm.
Formulation F1 showed the smallest droplets which were
9.10 lm and formulation F4 showed the largest droplets which
were 246.444 lm. For formulation F1 90% droplet was within
153.176 lm, 50% droplet was within 50.959 lm and 10%
droplet was within 9.100 lm. In this formulation 50% transcu-
tol HP and 50% tween-80 were used which produced a very
clear emulsion when water was added with agitation.
Formulation F2 produces larger particle size (90% droplet
was within 170.647 lm, 50% droplet was within 105.961 lm
and 10% droplet was within 29.968 lm). In this formulation
higher amount of tween-80 (65%) was used.
Behavior of formulation F3 was the same as of F2. In this
formulation we also used higher concentration tween-80
(75%). Droplet size was larger than F1 and F2 (90% droplet
was within 220.505 lm, 50% droplet was within 129.577 lm
and 10% droplet was within 68.642 lm).
Formulations F4 and F5 were also produced in larger drop-
let sizes than F1 although higher amounts of transcutol HP
were used in these formulations. So we can conclude that only
formulation F1 containing 50% transcutol HP and 50%
tween-80 produced SEDDS with lower droplet size.Table 2 Accuracy and precision results of the HPLC valida-
tion method.
Validation parameters Gliclazide
Accuracy % Recovery 99.94 ± 0.67
%RSD 0.67%
Precision Repeatability 0.65%
(%RSD) Ruggedness 0.69%3.5. Release of active gliclazide in different media
In-vitro dissolution study of gliclazide was carried out in a USP
Type II (paddle type) dissolution apparatus (Electrolab, India)
using 10 mg gliclazide. Distilled water, buffer solutions of pH
1.2, pH 4.5 and pH 6.8 were used as dissolution media that
were maintained at 37 ± 0.5 C and stirred at 100 rpm. From
the release study, it was found that the release rate of pure gli-
clazide was higher in buffer of pH 6.8 (75.141% within
40 min), due to the higher solubility of gliclazide in pH 6.8
(Bala et al., 2012). In other pH media (1.2 and 4.5), drug re-
lease was relatively lower (Fig. 2). This may be due to the
pH dependent solubility of gliclazide. In distilled water glicla-
zide is slightly soluble and accordingly the release rate of glicla-
zide in distilled water was found to be lower (33.407% within
40 min).
3.6. In-vitro release proﬁle of gliclazide from SEDDS
formulations and marketed products
F1 formulation containing 1:1 (m/m) mixture of Transcutol
HP/Tween-80 showed higher in-vitro drug release than other
formulations (Fig. 3). Within 20 min 99% drug was released.
This may be due to the small droplet size produced in the
emulsion. Drug release from F2 formulation was lower than
formulation F1. Within 30 min only 61% drug was released.
This is due to the higher droplet size. So the drug release rate
was found to depend on the droplet size of emulsion. DropletFigure 2 Dissolution proﬁle of gliclazide in different media
(n= 6).
Figure 4 Permeability proﬁle of gliclazide (n= 3).
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and Albert, 2008). Drug release from formulation F3 was low-
er than formulation F1 but higher than F2. Within 30 min
84% drug was released. Drug release from formulation F4
was lower than formulation F1 and F3 but higher than F2.
Within 30 min 78% drug was released. Drug release from F5
formulation was lower than formulation F1 but higher than
F2, F3 and F4. Within 30 min 97% drug was released.
Dissolution proﬁles of gliclazide immediate release tablets
of two Brands (A and B) were also studied for comparison
with SEDDS formulation. These two brands (A and B) re-
leased at 61% and 76% respectively within 30 min. This type
of inter brand dissolution variation is common for water insol-
uble drugs (Oishi et al., 2011). Brand B may contain an alkal-
izing agent that may be responsible for better dissolution rate
(Srivastav et al., 2011). On the other hand F1 formulation re-
leased 99% drug within 20 min and the pure gliclazide released
65.49% within 30 min. So from this study it was found that the
drug release from SEDDS formulation of gliclazide was higher
than that of market products and pure drug.
3.7. Permeability of gliclazide from SEDDS through chicken
intestinal sac
In addition to conventional dissolution testing of SEDDS, ex-
vivo permeability of gliclazide from SEDDS through chicken
intestinal sac was studied. Drug diffusion studies using pre-
treated cellulose dialysis tubing have been well documented
in the literature (Patil et al., 2007). Tukker (2000) described
deferent methods for drug diffusion study by using the intes-
tines of several animal species. Uses of chicken intestinal sac
for permeability study are also reported earlier (Kale et al.,
2007; Dias et al., 2010). In this study we used the chicken intes-
tinal sac due to its higher thickness which makes it suitable for
comparative permeability studies. Permeability proﬁles of dif-
ferent used samples did not show any signiﬁcant differences
during the initial 30 min. However, at the end of 5 h, formula-
tion F1 showed about 97.6% diffusion against 99.26% from
the drug solution in methanol. On the other hand pure glicla-
zide showed only 70% diffusion with in 5 h (Fig. 4).Figure 3 Dissolution proﬁle of gliclazide from pure drug,
SEDDS and marketed brands (n= 6).3.8. Effect of pure gliclazide and SEDDS of gliclazide on the
blood glucose level of mice
Pharmacodynamic marker parameters are often used to evalu-
ate the in-vivo performance of different classes of drugs. Glicla-
zide is an anti-diabetic drug and it decreases the plasma
glucose level. Hence plasma glucose level was used as a basis
for the comparison of in-vivo performance of SEDDS of glicla-
zide. Oral glucose loading animal model reported by Etuk
(2010) was used in this study. Plasma glucose level was found
to increase sharply in the case of glucose administration. But
Simultaneous administration of glucose and pure gliclazide de-
creased plasma glucose level slowly after the initial increase of
the glucose level. Then the glucose level again increased. But
when we administered the SEDDS (F1) along with glucose,
the plasma glucose level decreased rapidly.
Statistical analysis of the plasma glucose level was per-
formed to ascertain the effect of SEDDS formulation over
pure drug using one-way analysis of variance (ANOVA, signif-
icance level p< 0.05) while the results were conﬁrmed by Bon-
ferroni’s multiple comparison as a post hoc test. The analyses
were undertaken for plasma glucose level at three time points
(1–3 h). The results of ANOVA indicate that plasma glucose
level due to administration of SEDDS and pure gliclazide
was signiﬁcantly different at the three time points at 0.05 level.
From these observations, it can be concluded that SEDDS of
gliclazide are more effective than pure gliclazide to lower plas-
ma glucose level. This is due to the higher absorption of the
drug from SEDDS formulation.
4. Conclusion
SEDDS formulations consist of oils, surfactants and cosurfac-
tants, which are emulsiﬁed by aqueous medium under gentle
digestive motility in the gastrointestinal tract. It is considered
that the excipients in SEDDS could increase the dissolution
and permeability of the drug signiﬁcantly by decreasing the
348 T.S. Nipun, S.M. Ashraful Islamdroplet size. Gliclazide is a poorly aqueous soluble drug. The
low bioavailability of gliclazide is due to its poor solubility.
In this paper, we prepared gliclazide SEDDS formulations
and assessed the dissolution in-vitro; permeability through
chicken intestinal sac and in-vivo performance in mice. The
concentration of gliclazide in various excipients was analyzed
ﬁrst. Then SEDDS was prepared and the droplet size of the
emulsion was determined by Laser Diffraction Technology
of Malvern. Optimal formulations containing 1:1 (m/m) mix-
ture of Transcutol HP/Tween-80 showed a minimum droplet
size, higher in-vitro drug release, optimal drug diffusion, and
better control of plasma glucose level in mice. Our study indi-
cates that the potential use of SEDDS for the oral delivery of
gliclazide can be an alternative to improve its systemic
availability.References
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